ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

ABT Abbott Laboratories

105.50
-0.47 (-0.44%)
02 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Abbott Laboratories NYSE:ABT NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  -0.47 -0.44% 105.50 107.16 105.91 106.43 4,096,958 01:00:00

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abbott Laboratories - ABT

13/10/2016 11:40pm

PR Newswire (US)


Abbott Laboratories (NYSE:ABT)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Abbott Laboratories Charts.

NEW YORK, Oct. 13, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abbott Laboratories ("Abbott" or the "Company") (NYSE: ABT) (ISIN: US0028241000). Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Abbott and certain of its officers and/or directors have violated the federal securities laws.

[Click here to join a class action]

On April 28, 2016, Abbott issued a press release announcing a definitive agreement to acquire St. Jude Hospitals, Inc. ("St. Jude"), citing St. Jude's "strong positions in heart failure devices, atrial fibrillation and cardiac rhythm management." On October 11, 2016, pre-market, St. Jude issued a letter to physicians and patients warning that batteries on thousands of the Company's implantable defibrillators can quickly and unexpectedly deplete. St. Jude stated that two people had died after their devices failed to work correctly because of the drained battery, while 47 others reported dizziness or fainting. The warning applies to devices made before May 2015, which are in use by roughly 350,000 people worldwide. Abbott stated that the Company still expects to close its acquisition of St. Jude by the end of this year. 

On this news, Abbott stock fell $2.34, or 5.38%, to close at $41.16 on October 11, 2016.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-abbott-laboratories--abt-300344794.html

SOURCE Pomerantz LLP

Copyright 2016 PR Newswire

1 Year Abbott Laboratories Chart

1 Year Abbott Laboratories Chart

1 Month Abbott Laboratories Chart

1 Month Abbott Laboratories Chart

Your Recent History

Delayed Upgrade Clock